Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot Password? Reset your password

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login (Shibboleth)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Table of Contents
Vol. 20, No. 4, 2005
Issue release date: September 2005
Section title: Original Research Article
Dement Geriatr Cogn Disord 2005;20:238–244

A Volumetric Magnetic Resonance Imaging Study of the Amygdala in Frontotemporal Lobar Degeneration and Alzheimer’s Disease

Whitwell J.L.a, b · Sampson E.L.a, c · Watt H.C.a, d · Harvey R.J.a, e · Rossor M.N.a, f · Fox N.C.a
aDementia Research Centre, Institute of Neurology, University College London, London, UK; bDepartment of Diagnostic Radiology, Mayo Clinic, Rochester, Minn., USA; cDepartment of Mental Health Sciences, Royal Free and University College Medical School, London, UK; dMedical Statistics Unit, London School of Hygiene and Tropical Medicine, London, UK; eDepartment of Clinical and Biomedical Science, University of Melbourne, Melbourne, Australia; fDivision of Neuroscience and Psychological Medicine, Imperial College London, London, UK
email Corresponding Author

Prof. Nick Fox

Dementia Research Centre, National Hospital for Neurology and Neurosurgery

8–11 Queen Square, London WC1N 3BG (UK)

Tel. +44 207 829 8773, Fax +44 207 676 2066

E-Mail nfox@dementia.ion.ucl.ac.uk

Do you have an account?

Login Information

Contact Information

I have read the Karger Terms and Conditions and agree.


The amygdala is severely atrophied at post-mortem in frontotemporal lobar degeneration (FTLD), and may contribute to the prominent behavioural changes that are early features of FTLD. The aim of this study was to assess amygdala atrophy using MRI in the main syndromic variants of FTLD and Alzheimer’s disease (AD). Brain and amygdala volumes, adjusted for intracranial volume, were measured on 46 clinically diagnosed FTLD patients [22 frontal variant FTD (FTD), 14 semantic dementia (SD), 10 progressive non-fluent aphasia (PNFA)], 20 AD patients, and 17 controls. While severe amygdala atrophy was present in both FTLD (41% smaller than controls on the left; 33% on the right) and in AD (22% on the left; 19% on the right), the FTLD group had significantly greater amygdala atrophy (z = 3.21, p = 0.001 left, z = 2.50, p = 0.01 right) and left/right asymmetry (z = 2.03, p = 0.04) than AD. Amygdala atrophy was greater in SD than FTD, PNFA and AD (p < 0.02 for all). Highly asymmetrical atrophy was present in SD, greater on the left (z = 3.23, p = 0.001), and to a lesser extent in PNFA. Despite an overlap between clinical and radiological features of FTLD and AD, marked amygdala atrophy points towards a diagnosis of FTLD, with left greater than right atrophy suggestive of one of the language variants.

© 2005 S. Karger AG, Basel

Article / Publication Details

First-Page Preview
Abstract of Original Research Article

Received: June 02, 2005
Published online: September 12, 2005
Issue release date: September 2005

Number of Print Pages: 7
Number of Figures: 2
Number of Tables: 3

ISSN: 1420-8008 (Print)
eISSN: 1421-9824 (Online)

For additional information: http://www.karger.com/DEM

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.